CHICAGO — Decreasing vitamin A dimerization may be a promising treatment avenue for treating geographic atrophy, according to a speaker here.
In his presentation at Retina Subspecialty Day at the American Academy of Ophthalmology meeting, Alexander Melamud, MD, unveiled topline results from the phase 3 SAGA study investigating the efficacy, safety and pharmacokinetics of oral gildeuretinol, a form of deuterated vitamin A, in patients with GA.
“Vitamin A dimerization has been implicated in the formation of lipofuscin and [retinal pigment epithelium] and photoreceptor degeneration,”